ION Acquisition Corp 3 Ltd. (IACC) News

ION Acquisition Corp 3 Ltd. (IACC): $10.04

-0.01 (-0.10%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter IACC News Items

IACC News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest IACC News From Around the Web

Below are the latest news stories about ION ACQUISITION CORP 3 LTD that investors may wish to consider to help them evaluate IACC as an investment opportunity.

Day One Receives Orphan Designation from the European Commission for DAY101 for the Treatment of Glioma

SOUTH SAN FRANCISCO, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, today announced that the European Commission has granted orphan designation for the Company’s lead product candidate, DAY101, for the treatment of glioma. The designation was based on a positive opinion from the European Medicines Agency Commit

Yahoo | June 21, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5812 seconds.